This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington (DC): National Academies Press (US); 2017 [displayed 14 September 2023]. Available at https://www.ncbi.nlm.nih.gov/books/NBK423845/National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on the Health Effects of Marijuana: An Evidence Review and Research Agenda. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington (DC): National Academies Press (US); 2017[displayed 14 September 2023]. Available at https://www.ncbi.nlm.nih.gov/books/NBK423845/Search in Google Scholar
Hernandez-Unzueta I, Benedicto A, Olaso E, Sanz E, Viera C, Arteta B, Márquez J. Ocoxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver. Oncol Lett 2017;13:4002–12. doi: 10.3892/ol.2017.6016Hernandez-UnzuetaIBenedictoAOlasoESanzEVieraCArtetaBMárquezJ. Ocoxin oral solution® as a complement to irinotecan chemotherapy in the metastatic progression of colorectal cancer to the liver. Oncol Lett2017;13:4002–12. doi: 10.3892/ol.2017.6016Open DOISearch in Google Scholar
Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Canc Treat Rev 2008;34:656–69. doi: 10.1016/j.ctrv.2008.05.002KweekelDGuchelaarHJGelderblomH. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Canc Treat Rev2008;34:656–69. doi: 10.1016/j.ctrv.2008.05.002Open DOISearch in Google Scholar
Velasco G, Hernández-Tiedra S, Dávila D, Lorente M. The use of cannabinoids as anticancer agents. Prog Neuropsychopharmacol Biol Psychiatry 2016;64:259–66. doi: 10.1016/j.pnpbp.2015.05.010VelascoGHernández-TiedraSDávilaDLorenteM. The use of cannabinoids as anticancer agents. Prog Neuropsychopharmacol Biol Psychiatry2016;64:259–66. doi: 10.1016/j.pnpbp.2015.05.010Open DOISearch in Google Scholar
Guzmán M. Cannabis for the management of cancer symptoms: THC Version 2.0? Cannabis Cannabinoid Res 2018;3:117–9. doi: 10.1089/can.2018.0009GuzmánM. Cannabis for the management of cancer symptoms: THC Version 2.0?Cannabis Cannabinoid Res2018;3:117–9. doi: 10.1089/can.2018.0009Open DOISearch in Google Scholar
Cinnamon Bidwell L, York Williams SL, Mueller RL, Bryan AD, Hutchison KE. Exploring cannabis concentrates on the legal market: User profiles, product strength, and health-related outcomes. Addict Behav Rep 2018;8:102–6. doi: 10.1016/j.abrep.2018.08.004Cinnamon BidwellLYork WilliamsSLMuellerRLBryanADHutchisonKE. Exploring cannabis concentrates on the legal market: User profiles, product strength, and health-related outcomes. Addict Behav Rep2018;8:102–6. doi: 10.1016/j.abrep.2018.08.004Open DOISearch in Google Scholar
Mathijssen RHJ, Van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182–94. PMID: 11489791MathijssenRHJVan AlphenRJVerweijJLoosWJNooterKStoterGSparreboomA. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res2001;7:2182–94. PMID: 11489791Search in Google Scholar
Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, Yokoi T, Kamataki T. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996;56:3752–7. PMID: 8706020TakasunaKHagiwaraTHirohashiMKatoMNomuraMNagaiEYokoiTKamatakiT. Involvement of β-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res1996;56:3752–7. PMID: 8706020Search in Google Scholar
Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003;42:327–59. doi: 10.2165/00003088-200342040-00003GrotenhermenF. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet2003;42:327–59. doi: 10.2165/00003088-200342040-00003Open DOISearch in Google Scholar
Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers 2007;4:1770–804. doi: 10.1002/cbdv.200790152HuestisMA. Human cannabinoid pharmacokinetics. Chem Biodivers2007;4:1770–804. doi: 10.1002/cbdv.200790152Open DOISearch in Google Scholar
Smith NF, Figg WD, Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 2006;20:163–75. doi: 10.1016/j.tiv.2005.06.045SmithNFFiggWDSparreboomA. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro2006;20:163–75. doi: 10.1016/j.tiv.2005.06.045Open DOISearch in Google Scholar
Holland ML, Lau DTT, Allen JD, Arnold JC. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br J Pharmacol 2007;152:815–24. doi: 10.1038/sj.bjp.0707467HollandMLLauDTTAllenJDArnoldJC. The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br J Pharmacol2007;152:815–24. doi: 10.1038/sj.bjp.0707467Open DOISearch in Google Scholar
Bouquié R, Deslandes G, Mazaré H, Cogné M, Mahé J, Grégoire M, Jolliet P. Cannabis and anticancer drugs: societal usage and expected pharmacological interactions - a review. Fundam Clin Pharmacol 2018;32:462–84. doi: 10.1111/fcp.12373BouquiéRDeslandesGMazaréHCognéMMahéJGrégoireMJollietP. Cannabis and anticancer drugs: societal usage and expected pharmacological interactions - a review. Fundam Clin Pharmacol2018;32:462–84. doi: 10.1111/fcp.12373Open DOISearch in Google Scholar
Kopjar N, Fuchs N, Brčić Karačonji I, Žunec S, Katić A, Kozina G, Lucić Vrdoljak A. High Doses of Δ9-tetrahydrocannabinol might impair irinotecan chemotherapy: A review of potentially harmful interactions. Clin Drug Investig 2020;40:775–87. doi: 10.1007/s40261-020-00954-yKopjarNFuchsNBrčić KaračonjiIŽunecSKatićAKozinaGLucić VrdoljakA. High Doses of Δ9-tetrahydrocannabinol might impair irinotecan chemotherapy: A review of potentially harmful interactions. Clin Drug Investig2020;40:775–87. doi: 10.1007/s40261-020-00954-yOpen DOISearch in Google Scholar
Prester L, Mikolić A, Jurič A, Fuchs N, Neuberg M, Lucić Vrdoljak A, Brčić Karačonji I. Effects of Δ9-tetrahydrocannabinol on irinotecan-induced clinical effects in rats. Chem Biol Interact 2018;294:128–34. doi: 10.1016/j.cbi.2018.08.009PresterLMikolićAJuričAFuchsNNeubergMLucić VrdoljakABrčić KaračonjiI. Effects of Δ9-tetrahydrocannabinol on irinotecan-induced clinical effects in rats. Chem Biol Interact2018;294:128–34. doi: 10.1016/j.cbi.2018.08.009Open DOISearch in Google Scholar
Lucić Vrdoljak A, Fuchs N, Mikolić A, Žunec S, Brčić Karačonji I, Jurič A, Prester Lj, Micek V, Neuberg M, Čanović S, Mršić G, Kopjar N. Irinotecan and Δ9-tetrahydrocannabinol interactions in rat liver: a preliminary evaluation using biochemical and genotoxicity markers. Molecules 2018;23:1332. doi: 10.3390/molecules23061332Lucić VrdoljakAFuchsNMikolićAŽunecSBrčić KaračonjiIJuričAPresterLjMicekVNeubergMČanovićSMršićGKopjarN. Irinotecan and Δ9-tetrahydrocannabinol interactions in rat liver: a preliminary evaluation using biochemical and genotoxicity markers. Molecules2018;23:1332. doi:10.3390/molecules23061332Open DOISearch in Google Scholar
Zakon o zaštiti životinja [Animal protection act, in Croatian]. Službeni list 102/2017.Zakon o zaštiti životinja [Animal protection act, in Croatian]. Službeni list102/2017.Search in Google Scholar
ARRIVE. The ARRIVE guidelines 2.0 [displayed 14 September 2023]. Available at https://arriveguidelines.org/sites/arrive/files/documents/ARRIVE%20guidelines%202.0%20-%20English.pdfARRIVE. The ARRIVE guidelines 2.0[displayed 14 September 2023]. Available at https://arriveguidelines.org/sites/arrive/files/documents/ARRIVE%20guidelines%202.0%20-%20English.pdfSearch in Google Scholar
Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes [displayed 14 September 2023]. Available at https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:0079:en:PDFDirective 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes[displayed 14 September 2023]. Available at https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:0079:en:PDFSearch in Google Scholar
Hardman WE, Moyer MP, Cameron IL. Efficacy of treatment of colon, lung and breast human carcinoma xenografts with: doxorubicin, cisplatin, irinotecan or topotecan. Anticancer Res 1999;19:2269–74. PMID: 10472342HardmanWEMoyerMPCameronIL. Efficacy of treatment of colon, lung and breast human carcinoma xenografts with: doxorubicin, cisplatin, irinotecan or topotecan. Anticancer Res1999;19:2269–74. PMID: 10472342Search in Google Scholar
Hardman WE, Moyer MP, Cameron IL. Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice. Br J Cancer 2002;86:983–8. doi: 10.1038/sj.bjc.6600175HardmanWEMoyerMPCameronIL. Consumption of an omega-3 fatty acids product, INCELL AAFA, reduced side-effects of CPT-11 (irinotecan) in mice. Br J Cancer2002;86:983–8. doi: 10.1038/sj.bjc.6600175Open DOISearch in Google Scholar
Guichard S, Chatelut E, Lochon I, Bugat R, Mahjoubi M, Canal P. Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice. Cancer Chemother Pharmacol 1998;42:165–70. doi: 10.1007/s002800050801GuichardSChatelutELochonIBugatRMahjoubiMCanalP. Comparison of the pharmacokinetics and efficacy of irinotecan after administration by the intravenous versus intraperitoneal route in mice. Cancer Chemother Pharmacol1998;42:165–70. doi: 10.1007/s002800050801Open DOISearch in Google Scholar
Turner PV, Brabb T, Pekow C, Vasbinder MA. Administration of substances to laboratory animals: Routes of administration and factors to consider. J Am Assoc Lab Anim Sci 2011;50:600–13. PMID: 22330705TurnerPVBrabbTPekowCVasbinderMA. Administration of substances to laboratory animals: Routes of administration and factors to consider. J Am Assoc Lab Anim Sci2011;50:600–13. PMID: 22330705Search in Google Scholar
Zamboni WC, Houghton PJ, Thompson J, Cheshire PJ, Hanna SK, Richmond LB, Lou X, Stewart CF. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts. Clin Cancer Res 1998;4:455–62. PMID: 9516936ZamboniWCHoughtonPJThompsonJCheshirePJHannaSKRichmondLBLouXStewartCF. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts. Clin Cancer Res1998;4:455–62. PMID: 9516936Search in Google Scholar
Loflin M, Earleywine M. A new method of cannabis ingestion: The dangers of dabs? Addict Behav 2014;39:1430–3. doi: 10.1016/j.addbeh.2014.05.013LoflinMEarleywineM. A new method of cannabis ingestion: The dangers of dabs?Addict Behav2014;39:1430–3. doi: 10.1016/j.addbeh.2014.05.013Open DOISearch in Google Scholar
Ashton JC, Milligan ED. Cannabinoids for the treatment of neuropathic pain: clinical evidence. Curr Opin Invest Drugs 2008;9:65–75. PMID: 18183533AshtonJCMilliganED. Cannabinoids for the treatment of neuropathic pain: clinical evidence. Curr Opin Invest Drugs2008;9:65–75. PMID: 18183533Search in Google Scholar
Bridgeman MB, Abazia DT. Medicinal cannabis: History, pharmacology, and implications for the acute care setting. Pharm Ther 2017;42:180–8. PMID: 28250701BridgemanMBAbaziaDT. Medicinal cannabis: History, pharmacology, and implications for the acute care setting. Pharm Ther2017;42:180–8. PMID: 28250701Search in Google Scholar
Harvey DJ. Metabolism and pharmacokinetics of the cannabinoids. In: Watson RR, editor. Biochemistry and physiology of substance abuse. Boca Raton (FL): CRC Press; 1991. p. 279–365.HarveyDJ. Metabolism and pharmacokinetics of the cannabinoids. In: WatsonRReditor. Biochemistry and physiology of substance abuse. Boca Raton (FL): CRC Press; 1991. p. 279–365.Search in Google Scholar
Rella JG. Recreational cannabis use: pleasures and pitfalls. Cleve Clin J Med 2015;82:765–72. doi: 10.3949/ccjm.82a.14073RellaJG. Recreational cannabis use: pleasures and pitfalls. Cleve Clin J Med2015;82:765–72. doi: 10.3949/ccjm.82a.14073Open DOISearch in Google Scholar
Goullé JP, Saussereau E, Lacroix C. Delta-9-tetrahydrocannabinol pharmacokinetics. Ann Pharm Fr 2008;66:232–44. doi: 10.1016/j.pharma.2008.07.006GoulléJPSaussereauELacroixC. Delta-9-tetrahydrocannabinol pharmacokinetics. Ann Pharm Fr2008;66:232–44. doi: 10.1016/j.pharma.2008.07.006Open DOISearch in Google Scholar
Schwilke EW, Schwope DM, Karschner, EL, Lowe RH, Darwin WD, Kelly DL, Goodwin RS, Gorelick DA, Huestis MA. Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem 2009;55:2180–9. doi: 10.1373/clinchem.2008.122119SchwilkeEWSchwopeDMKarschnerELLoweRHDarwinWDKellyDLGoodwinRSGorelickDAHuestisMA. Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem2009;55:2180–9. doi: 10.1373/clinchem.2008.122119Open DOISearch in Google Scholar
McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manag 2005;10:15A–22A. doi: 10.1155/2005/242516McGilverayIJ. Pharmacokinetics of cannabinoids. Pain Res Manag2005;10:15A–22A. doi: 10.1155/2005/242516Open DOISearch in Google Scholar
Kim HJ, Kim SJ, Woo CW, Kim ST, Im M, Park SK, Kim JY, Yoo HJ, Woo DC, Kim JK. Treatment of chemotherapy-induced cachexia with BST204: a multimodal validation study. Metabolomics 2021;17(4):36. doi: 10.1007/s11306-021-01781-8KimHJKimSJWooCWKimSTImMParkSKKimJYYooHJWooDCKimJK. Treatment of chemotherapy-induced cachexia with BST204: a multimodal validation study. Metabolomics2021;17(4):36. doi:10.1007/s11306-021-01781-8Open DOISearch in Google Scholar
ARENA/OLAW. Institutional Animal Care and Use Committee Guidebook, 2002 [displayed 14 September 2023]. Available at https://olaw.nih.gov/sites/default/files/GuideBook.pdfARENA/OLAW. Institutional Animal Care and Use Committee Guidebook, 2002[displayed 14 September 2023]. Available at https://olaw.nih.gov/sites/default/files/GuideBook.pdfSearch in Google Scholar
Rodriguez-Gonzalez JC, Hernández-Balmaseda I, Declerck K, Pérez-Novo C, Logie E, Theys C, Jakubek P, Quiñones-Maza OL, Dantas-Cassali G, Carlos Dos Reis D, Van Camp G, Lopes Paz MT, Rodeiro-Guerra I, Delgado-Hernández R, Vanden Berghe W. Antiproliferative, antiangiogenic, and antimetastatic therapy response by mangiferin in a syngeneic immunocompetent colorectal cancer mouse model involves changes in mitochondrial energy metabolism. Front Pharmacol 2021;12:670167. doi: 10.3389/fphar.2021.670167Rodriguez-GonzalezJCHernández-BalmasedaIDeclerckKPérez-NovoCLogieETheysCJakubekPQuiñones-MazaOLDantas-CassaliGCarlos Dos ReisDVan CampGLopes PazMTRodeiro-GuerraIDelgado-HernándezRVanden BergheW. Antiproliferative, antiangiogenic, and antimetastatic therapy response by mangiferin in a syngeneic immunocompetent colorectal cancer mouse model involves changes in mitochondrial energy metabolism. Front Pharmacol2021;12:670167. doi:10.3389/fphar.2021.670167Open DOISearch in Google Scholar
Kašuba V, Tariba Lovaković B, Lucić Vrdoljak A, Katić A, Kopjar N, Micek V, Milić M, Pizent A, Želježić D, Žunec S. Evaluation of toxic effects induced by sub-acute exposure to low doses of α-cypermethrin in adult male rats. Toxics 2022;10:717. doi: 10.3390/toxics10120717KašubaVTariba LovakovićBLucić VrdoljakAKatićAKopjarNMicekVMilićMPizentAŽelježićDŽunecS. Evaluation of toxic effects induced by sub-acute exposure to low doses of α-cypermethrin in adult male rats. Toxics2022;10:717. doi:10.3390/toxics10120717Open DOISearch in Google Scholar
Ellman GL, Courtney KD, Andres V Jr, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88–95. doi: 10.1016/0006-2952(61)90145-9EllmanGLCourtneyKDAndresVJrFeatherstoneRM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol1961;7:88–95. doi: 10.1016/0006-2952(61)90145-9Open DOISearch in Google Scholar
Katalinić M, Maček Hrvat N, Zdarova Karasová J, Misik J, Kovarik Z. Translation of in vitro to in vivo pyridinium oxime potential in tabun poisoning. Arh Hig Rada Toksikol 2015;66:291–8. doi: 10.1515/aiht-2015-66-2740KatalinićMMaček HrvatNZdarova KarasováJMisikJKovarikZ. Translation of in vitro to in vivo pyridinium oxime potential in tabun poisoning. Arh Hig Rada Toksikol2015;66:291–8. doi: 10.1515/aiht-2015-66-2740Open DOISearch in Google Scholar
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351–8. doi: 10.1016/0003-2697(79)90738-3OhkawaHOhishiNYagiK. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem1979;95:351–8. doi: 10.1016/0003-2697(79)90738-3Open DOISearch in Google Scholar
Socci DJ, Bjugstad KB, Jones HC, Pattisapu JV, Arendash GW. Evidence that oxidative stress is associated with the pathophysiology of inherited hydrocephalus in the H-Tx rat model. Exp Neurol 1999;155:109–17. doi: 10.1006/exnr.1998.6969SocciDJBjugstadKBJonesHCPattisapuJVArendashGW. Evidence that oxidative stress is associated with the pathophysiology of inherited hydrocephalus in the H-Tx rat model. Exp Neurol1999;155:109–17. doi: 10.1006/exnr.1998.6969Open DOISearch in Google Scholar
Kamencic H, Lyon A, Paterson PG, Juurlink BH. Monochlorobimane fluorometric method to measure tissue glutathione. Anal Biochem 2000;286:35–7. doi: 10.1006/abio.2000.4765KamencicHLyonAPatersonPGJuurlinkBH. Monochlorobimane fluorometric method to measure tissue glutathione. Anal Biochem2000;286:35–7. doi: 10.1006/abio.2000.4765Open DOISearch in Google Scholar
Yamamoto M, Kurita A, Asahara T, Takakura A, Katono K, Iwasaki M, Ryuge S,Wada M, Onoda S, Yanaihara T, Yokoba M, Mitsufuji H, Nishii Y, Fukui T, Masuda N. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats. Oncol Rep 2008;20:727–30. PMID: 18813810YamamotoMKuritaAAsaharaTTakakuraAKatonoKIwasakiMRyugeSWadaMOnodaSYanaiharaTYokobaMMitsufujiHNishiiYFukuiTMasudaN. Metabolism of irinotecan and its active metabolite SN-38 by intestinal microflora in rats. Oncol Rep2008;20:727–30. PMID: 18813810Search in Google Scholar
Houghton PJ, Cheshire PJ, Hallman Jr JD, Lutz L, Friedman HS, Danks MK, Houghton JA. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393–403. doi: 10.1007/BF00686188HoughtonPJCheshirePJHallmanJDJrLutzLFriedmanHSDanksMKHoughtonJA. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol1995;36:393–403. doi: 10.1007/BF00686188Open DOISearch in Google Scholar
Thompson J, Zamboni WC, Cheshire PJ, Lutz L, Luo X, Li Y, Houghton JA, Stewart CF, Houghton PJ. Efficacy of systematic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 1997;3:423–31. PMID: 9815701ThompsonJZamboniWCCheshirePJLutzLLuoXLiYHoughtonJAStewartCFHoughtonPJ. Efficacy of systematic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res1997;3:423–31. PMID: 9815701Search in Google Scholar
Zhu LX, Sharma S, Stolina M, Gardner B, Roth MD, Tashkin DP, Dubinett SM. Δ9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 2000;165:373–80. doi: 10.4049/jimmunol.165.1.373ZhuLXSharmaSStolinaMGardnerBRothMDTashkinDPDubinettSM. Δ9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol2000;165:373–80. doi: 10.4049/jimmunol.165.1.373Open DOISearch in Google Scholar
Zhong W, Myers JS, Wang F, Wang K, Lucas J, Rosfjord E, Lucas J, Hooper AT, Yang S, Lemon LA, Guffroy M, May C, Bienkowska JR, Rejto PA. Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors. BMC Genomics 2020;21(1):2. doi: 10.1186/s12864-019-6344-3ZhongWMyersJSWangFWangKLucasJRosfjordELucasJHooperATYangSLemonLAGuffroyMMayCBienkowskaJRRejtoPA. Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors. BMC Genomics2020;21(1):2. doi:10.1186/s12864-019-6344-3Open DOISearch in Google Scholar
Montenegro MF, Nieto-Cero´n S, Ruiz-Espejo F, de la Cadena MP, Rodriguez-Berrocal FJ, Vidal CJ. Cholinesterase activity and enzyme components in healthy and cancerous human colorectal sections. Chem Biol Interact 2005;157–8:429–30. doi: 10.1016/j.cbi.2005.10.091MontenegroMFNieto-Cero´nSRuiz-EspejoFde la CadenaMPRodriguez-BerrocalFJVidalCJ. Cholinesterase activity and enzyme components in healthy and cancerous human colorectal sections. Chem Biol Interact2005;157–8:429–30. doi: 10.1016/j.cbi.2005.10.091Open DOISearch in Google Scholar
Vidal CJ. Expression of cholinesterases in brain and non-brain tumours. Chem Biol Interact 2005;15–8:227–32. doi: 10.1016/j.cbi.2005.10.035VidalCJ. Expression of cholinesterases in brain and non-brain tumours. Chem Biol Interact2005;15–8:227–32. doi: 10.1016/j.cbi.2005.10.035Open DOISearch in Google Scholar
Battisti V, Bagatini MD, Maders LD, Chiesa J, Santos KF, Gonçalves JF, Abdalla FH, Battisti IE, Schetinger MR, Morsch VM. Cholinesterase activities and biochemical determinations in patients with prostate cancer: influence of Gleason score, treatment and bone metastasis. Biomed Phar macother 2012;66:249–55. doi: 10.1016/j.biopha.2011.11.005BattistiVBagatiniMDMadersLDChiesaJSantosKFGonçalvesJFAbdallaFHBattistiIESchetingerMRMorschVM. Cholinesterase activities and biochemical determinations in patients with prostate cancer: influence of Gleason score, treatment and bone metastasis. Biomed Phar macother2012;66:249–55. doi: 10.1016/j.biopha.2011.11.005Open DOISearch in Google Scholar
Kimura S, Soria F, D’Andrea D, Foerster B, Abufaraj M, Vartolomei MD, Karakiewicz PI, Mathieu R, Moschini M, Rink M, Egawa S, Shariat SF, Gust KM. Prognostic value of serum cholinesterase in non-muscle-invasive bladder cancer. Clin Genitourin Cancer 2018;16(6):e1123–32. doi: 10.1016/j.clgc.2018.07.002KimuraSSoriaFD’AndreaDFoersterBAbufarajMVartolomeiMDKarakiewiczPIMathieuRMoschiniMRinkMEgawaSShariatSFGustKM. Prognostic value of serum cholinesterase in non-muscle-invasive bladder cancer. Clin Genitourin Cancer2018;16(6):e1123–32. doi: 10.1016/j.clgc.2018.07.002Open DOISearch in Google Scholar
Dodds HM, Bishop JF, Rivory LP. More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin. J Natl Cancer Inst 1999;91:91–2. doi: 10.1093/jnci/91.1.91aDoddsHMBishopJFRivoryLP. More about: irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin. J Natl Cancer Inst1999;91:91–2. doi: 10.1093/jnci/91.1.91aOpen DOISearch in Google Scholar
Eubanks LM, Rogers CJ, Beuscher AE, Koob GF, Olson AJ, Dickerson TJ, Janda K. A molecular link between the active component of marijuana and Alzheimer disease patologhy. Mol Pharm 2006;3:773–7. doi: 10.1021/mp060066mEubanksLMRogersCJBeuscherAEKoobGFOlsonAJDickersonTJJandaK. A molecular link between the active component of marijuana and Alzheimer disease patologhy. Mol Pharm2006;3:773–7. doi: 10.1021/mp060066mOpen DOISearch in Google Scholar
Perillo B, Di Donato M, Pezone, Di Zazzo E, Giovannelli P, Galasso G, Castoria G, Migliaccio A. ROS in cancer therapy: the bright side of the moon. Exp Mol Med 2020;52:192–203. doi: 10.1038/s12276-020-0384-2PerilloBDi DonatoMPezoneDi ZazzoEGiovannelliPGalassoGCastoriaGMigliaccioA. ROS in cancer therapy: the bright side of the moon. Exp Mol Med2020;52:192–203. doi: 10.1038/s12276-020-0384-2Open DOISearch in Google Scholar
Pavlek LR, Dillard J, Rogers LK. The role of oxidative stress in toxicities due to drugs of abuse. Curr Opin Toxicol 2020;20–21:29–35. doi: 10.1016/j.cotox.2020.04.003PavlekLRDillardJRogersLK. The role of oxidative stress in toxicities due to drugs of abuse. Curr Opin Toxicol2020;20–21:29–35. doi: 10.1016/j.cotox.2020.04.003Open DOISearch in Google Scholar
Rtibi K, Selmi S, Grami D, Sebai H, Amri M, Marzouki L. Irinotecan chemotherapy-induced intestinal oxidative stress: Underlying causes of disturbed mucosal water and electrolyte transport. Pathophysiology 2017;24:275–9. doi: 10.1016/j.pathophys.2017.07.002RtibiKSelmiSGramiDSebaiHAmriMMarzoukiL. Irinotecan chemotherapy-induced intestinal oxidative stress: Underlying causes of disturbed mucosal water and electrolyte transport. Pathophysiology2017;24:275–9. doi: 10.1016/j.pathophys.2017.07.002Open DOISearch in Google Scholar
, , , , , , , oraz | 30 wrz 2023